AON heads into the week with an unusual split between what options traders are doing and what the stock itself is telling you — calls spiking while the price drifts lower.
The options signal is the standout this week. Call demand has surged sharply, with the put/call ratio dropping to 0.62 — more than three standard deviations below its 20-day average of 0.82. That's the most bullish options lean AON has seen in the past year, against a 52-week PCR range of 0.20 to 1.04. The timing is notable: the stock has fallen 3.7% on the week and 6.5% over the past month to $343.20, so this isn't a call-buying frenzy chasing a momentum trade. It looks more like positioning for a mean-reversion play, or selective accumulation ahead of the October 30 earnings date.
Short positioning tells a quiet, uncrowded story. Short interest has drifted lower, declining roughly 7% over the past month to 1.8% of the free float — a structurally low level that has never been a primary driver for this stock. Borrow availability remains extremely loose at over 3,600% of short interest, meaning there is far more lending capacity than current demand warrants. Cost to borrow has ticked up 13% on the week and 30% over the month to around 0.44% annualised, but that remains firmly in "easy to borrow" territory. The ORTEX short score of 32 sits in the lower third of the universe — positioning here looks indifferent rather than aggressive in either direction.
The Street is broadly constructive, though the stock's recent slide is creating a widening gap to targets. Morgan Stanley lifted its price target to $410 this morning, maintaining Overweight, and that follows a string of post-Q2 target raises from Wells Fargo ($419), Citi ($435), Mizuho ($437), JP Morgan ($412), and Keefe Bruyette & Woods ($412) — nearly every firm that updated after earnings moved their number higher. The consensus mean target is now $404, implying roughly 18% upside from current levels. The lone sceptics are UBS (Neutral, $387) and Piper Sandler (Neutral, $391, downgraded from Overweight in July). The bull case centres on NFP integration delivering incremental organic growth and continued EBITDA margin expansion. The bear case flags P&C rate headwinds, slower Commercial Risk revenue, and execution risk on a deal the Street generally viewed as expensive. On valuation, the trailing PE has compressed to around 17.4x and EV/EBITDA to 13.8x as the stock has retreated — both multiples have eased over the past month, slightly softening the valuation argument against AON.
The institutional picture is stable, with BlackRock holding 7.4% and Vanguard around 7.0%, but JP Morgan Asset Management's last-reported position showed a notable addition of 5.6 million shares — the largest holder movement in the top-15 by some distance. On the insider side, General Counsel Darren Zeidel sold roughly 2,550 shares across three tranches in late July at prices between $370 and $380, well above the current level, adding a mild note of caution at those prices. CFO Edmund Reese received an equity award of 3,975 shares on July 1 and sold a portion (2,198 shares) the same day at $343.56 — essentially back where the stock is now.
AON's recent earnings history is consistent: the stock fell 3.9% the day after Q2 results in late July, and extended that to a 5.6% five-day drawdown. The prior event delivered a similar -2.4% / -2.3% pattern. The trend is two consecutive earnings prints followed by a multi-day drift lower — context worth holding as the stock re-approaches those same levels heading into October 30.
The tension worth watching is whether the sharp call-buying this week represents genuine conviction that the slide is overdone, or simply rolling hedges resetting after the latest drawdown — and whether the gap between current price and the cluster of analyst targets in the $400s begins to narrow before earnings.
See the live data behind this article on ORTEX.
Open AON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
